Literature DB >> 17440685

The effect of povidone iodine flush versus drops on conjunctival colonization before intravitreal injections.

Ammar Safar1, Monica C Dellimore.   

Abstract

BACKGROUND: To determine the most effective method of applying povidone iodine 5% to decrease conjunctival colonization before intravitreal injections.
METHODS: Twenty-eight patients from two tertiary care centers undergoing intravitreal injection for diffuse diabetic macular edema, exudative age-related macular degeneration, venous occlusive disease, or refractory pseudophakic cystoid macular edema were prospectively randomized to two study arms. One arm received 2-3 drops of 5% povidone iodine (drops group) and the second received a 10 ml flush of the same solution (flush group). The inferior conjunctival fornix was cultured before and after antiseptic technique was performed in all patients. Three culture media, thioglycollate broth, chocolate agar and blood agar, were used for each sample.
RESULTS: Each study group had 14 patients. Prior to antisepsis, 22 of the 28 (78.6%) subjects had positive conjunctival cultures. 16 and 14 bacterial organisms were isolated in the first and second groups, respectively. After using 2-3 drops of 5% povidone iodine in the first study arm of patients, three of 16 (18.7% reduction) bacterial organisms were no longer isolated in thioglycollate broth media. With flush irrigation of 10 ml of 5% povidone iodine, seven of 14 (50% reduction) bacterial organisms were no longer isolated (P-value 0.07) in broth media. No difference in reduction of bacterial colonization was found on plated media (chocolate agar and blood agar).
CONCLUSIONS: Irrigating the conjunctival fornix with 5% povidone iodine results in greater reduction of bacterial colonization compared with drop application of the same solution. Flush irrigation may provide better protection against the risk of endophthalmitis with intravitreal injections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440685     DOI: 10.1007/s10792-007-9073-6

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  17 in total

1.  Prospective randomized comparison of 2 different methods of 5% povidone-iodine applications for anterior segment intraocular surgery.

Authors:  Herminia Miño de Kaspar; Robert T Chang; Kuldev Singh; Peter R Egbert; Mark S Blumenkranz; Christopher N Ta
Journal:  Arch Ophthalmol       Date:  2005-02

2.  Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion.

Authors:  Ken Hayashi; Hideyuki Hayashi
Journal:  Am J Ophthalmol       Date:  2005-06       Impact factor: 5.258

3.  Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic.

Authors:  S J Isenberg; L Apt; R Yoshimori; S Khwarg
Journal:  Arch Ophthalmol       Date:  1985-09

4.  Povidone-iodine: its efficacy as a preoperative conjunctival and periocular preparation.

Authors:  D R Caldwell; P R Kastl; J Cook; J Simon
Journal:  Ann Ophthalmol       Date:  1984-06

5.  Chemical preparation of the eye in ophthalmic surgery. I. Effect of conjunctival irrigation.

Authors:  S Isenberg; L Apt; R Yoshimuri
Journal:  Arch Ophthalmol       Date:  1983-05

6.  Povidone-iodine as an ophthalmic antiseptic.

Authors:  G T Kiffney; A C Hattaway
Journal:  Surg Forum       Date:  1966

7.  Acute endophthalmitis following intravitreal triamcinolone acetonide injection.

Authors:  Darius M Moshfeghi; Peter K Kaiser; Ingrid U Scott; Jonathan E Sears; Matthew Benz; Juan P Sinesterra; Richard S Kaiser; Sophie J Bakri; Raj K Maturi; Jonathan Belmont; Paul M Beer; Timothy G Murray; Hugo Quiroz-Mercado; William F Mieler
Journal:  Am J Ophthalmol       Date:  2003-11       Impact factor: 5.258

8.  Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes.

Authors:  T M Aaberg; H W Flynn; J Schiffman; J Newton
Journal:  Ophthalmology       Date:  1998-06       Impact factor: 12.079

9.  Comparison of 5% povidone-iodine solution against 1% povidone-iodine solution in preoperative cataract surgery antisepsis: a prospective randomised double blind study.

Authors:  A W Ferguson; J A Scott; J McGavigan; R A Elton; J McLean; U Schmidt; R Kelkar; B Dhillon
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

10.  Intravitreal injection of triamcinolone for diffuse diabetic macular edema.

Authors:  Jost B Jonas; Ingrid Kreissig; Antje Söfker; Robert F Degenring
Journal:  Arch Ophthalmol       Date:  2003-01
View more
  5 in total

1.  Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis.

Authors:  Christian Clement; Joseph A Capriotti; Manish Kumar; Jeffery A Hobden; Timothy P Foster; Partha S Bhattacharjee; Hilary W Thompson; Rashed Mahmud; Bo Liang; James M Hill
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-21       Impact factor: 4.799

2.  Study of the Acute Effects of Povidone-Iodine on Conjunctival Bacterial Flora.

Authors:  Jeff H Pettey; Mark D Mifflin; Randall J Olson
Journal:  J Ocul Pharmacol Ther       Date:  2015-08-19       Impact factor: 2.671

Review 3.  Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review.

Authors:  Rohan Merani; Alex P Hunyor
Journal:  Int J Retina Vitreous       Date:  2015-07-21

Review 4.  Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections.

Authors:  P Et Lau; K S Jenkins; C J Layton
Journal:  J Ophthalmol       Date:  2018-07-24       Impact factor: 1.909

5.  Safety Measures for Maintaining Low Endophthalmitis Rate after Intravitreal Anti-Vascular Endothelial Growth Factor Injection before and during the COVID-19 Pandemic.

Authors:  Koji Tanaka; Hiroyuki Shimada; Ryusaburo Mori; Yorihisa Kitagawa; Hajime Onoe; Kazuki Tamura; Hiroyuki Nakashizuka
Journal:  J Clin Med       Date:  2022-02-07       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.